Modaheal represents a significant advancement in the field of wakefulness-promoting agents, offering a targeted solution for individuals experiencing excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Developed with pharmaceutical precision, this medication contains modafinil as its active ingredient, a compound renowned for its ability to enhance alertness without the typical stimulant side effects. Clinical evidence supports its efficacy in improving cognitive function, sustaining attention, and reducing fatigue in patients with diagnosed sleep-wake disorders. This product card provides comprehensive information for healthcare professionals considering Modaheal for appropriate patient populations.

Features

• Contains 100mg or 200mg modafinil per tablet
• Film-coated formulation for easier swallowing
• Extended duration of action (approximately 12-15 hours)
• Low abuse potential compared to traditional stimulants
• Minimal impact on natural sleep architecture when dosed appropriately
• Bioequivalent to reference listed drugs
• Manufactured in FDA-approved facilities

Benefits

• Promotes sustained wakefulness and alertness throughout waking hours
• Enhances cognitive performance including memory, attention, and executive function
• Reduces excessive daytime sleepiness in narcolepsy patients by up to 70%
• Improves quality of life for shift workers by facilitating adaptation to non-traditional schedules
• Demonstrates favorable safety profile with limited cardiovascular effects
• Provides predictable pharmacokinetics with once-daily dosing convenience

Common use

Modaheal is primarily indicated for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea (as adjunctive therapy to continuous positive airway pressure), and shift work sleep disorder. Off-label applications may include attention deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis, though these uses require careful clinical consideration. The medication works by selectively targeting wake-promoting pathways in the brain, particularly involving dopamine, norepinephrine, and orexin systems, without producing generalized CNS stimulation.

Dosage and direction

The recommended dosage for narcolepsy and obstructive sleep apnea is 200mg taken orally once daily in the morning. For shift work sleep disorder, 200mg should be taken approximately one hour before the start of the work shift. Treatment may be initiated at 100mg for patients who are elderly, debilitated, or have severe hepatic impairment. Tablets should be swallowed whole with water and may be taken with or without food, though food may delay absorption slightly. Dosage adjustments should be made under medical supervision based on efficacy and tolerability.

Precautions

Patients should be monitored for the development of rash or serious dermatological reactions, as modafinil has been associated with Stevens-Johnson syndrome in rare cases. Cardiovascular status should be assessed periodically, particularly in patients with pre-existing hypertension or cardiac conditions. Those with history of psychosis, depression, or mania should be closely observed for symptom exacerbation. Caution is advised when operating machinery or driving until the individual’s response to Modaheal is established. Regular assessment of continued need for therapy is recommended.

Contraindications

Modaheal is contraindicated in patients with known hypersensitivity to modafinil, armodafinil, or any component of the formulation. It should not be used in those with symptomatic ischemic heart disease, left ventricular hypertrophy, or mitral valve prolapse when accompanied by neurological symptoms. The medication is contraindicated in patients with history of cardiac arrhythmias, particularly those that required treatment. Use during pregnancy is contraindicated unless potential benefits outweigh risks, as animal studies have shown potential teratogenic effects.

Possible side effects

Common adverse reactions (≥5%) include headache (34%), nausea (11%), nervousness (7%), anxiety (5%), insomnia (5%), and dizziness (5%). Less frequently reported effects include dry mouth, diarrhea, constipation, and rhinitis. Serious but rare side effects may include psychiatric symptoms (mania, hallucinations, aggression), cardiovascular events (chest pain, palpitations), severe dermatological reactions, and angioedema. Most side effects are mild to moderate and often diminish with continued therapy.

Drug interaction

Modaheal may reduce the effectiveness of oral contraceptives by inducing cytochrome P450 3A4 enzymes—alternative contraceptive methods are recommended during and for one month after treatment. It may increase metabolism of cyclosporine, certain antidepressants, and anticonvulsants. Concurrent use with MAO inhibitors may increase blood pressure. Modaheal may potentiate effects of sympathomimetic medications. Dose adjustments may be necessary for drugs metabolized by CYP2C19, as modafinil inhibits this enzyme. Close monitoring is advised when co-administering with warfarin, phenytoin, or diazepam.

Missed dose

If a dose is missed, it should be taken as soon as possible unless it is close to the time for the next scheduled dose. Doubling the dose is not recommended. For shift work disorder, if the dose is missed and the work shift has already begun, the dose should be skipped to prevent interference with subsequent sleep periods. Patients should maintain a consistent dosing schedule to ensure optimal therapeutic effects.

Overdose

Symptoms of overdose may include insomnia, central nervous system excitation, agitation, anxiety, confusion, tachycardia, hypertension, and gastrointestinal distress. In cases of suspected overdose, symptomatic and supportive treatment should be initiated. Cardiovascular monitoring is recommended. There is no specific antidote for modafinil overdose. Hemodialysis does not significantly enhance elimination due to high protein binding. Cases of overdose should be reported to poison control centers for appropriate management guidance.

Storage

Store at controlled room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use if the seal is broken or tablets show signs of deterioration. Properly dispose of expired or unused medication through drug take-back programs.

Disclaimer

This information is intended for healthcare professionals and should not replace comprehensive clinical judgment. Prescribers should review full prescribing information before initiating therapy. Modaheal is available by prescription only and should be used only for FDA-approved indications or under careful off-label consideration. Individual patient response may vary, and treatment should be tailored to specific clinical circumstances. Regular follow-up and monitoring are essential for safe and effective use.

Reviews

Clinical studies demonstrate that 78% of narcolepsy patients reported significant improvement in daytime sleepiness with Modaheal therapy. In shift work disorder trials, 74% of patients showed improved ability to maintain nighttime alertness. Healthcare providers note the favorable side effect profile compared to traditional stimulants, with particular appreciation for the lack of significant rebound hypersomnia. Patients report improved work performance, social functioning, and overall quality of life. Long-term studies indicate maintained efficacy with continuous use for up to 40 weeks, though periodic evaluation of continued need is recommended.